Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
G Castello, P Comella, T Manzo, M Napolitano, A P Parziale, M G Galati, A Daponte, R Casaretti, E Celentano, G Comella
Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanomaMelanoma Res. 1993 Feb;3(1):43-9.
G Meloni, M Vignetti, E Pogliani, R Invernizzi, B Allione, S Mirto, S Sica, F Leoni, C Selleri, F Mandelli
Interleukin-2 therapy in relapsed acute myelogenous leukemiaCancer J Sci Am. 1997 Dec;3 Suppl 1:S43-7.
G Meloni, R Foà, S Tosti, M Vignetti, F Mancini, A Guarini, D Marchis, F Gavosto, F Mandelli
Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot studyLeukemia. 1992 Aug;6(8):780-5.
G R Weiss, K A Margolin, F R Aronson, M Sznol, M B Atkins, J P Dutcher, E R Gaynor, D H Boldt, J H Doroshow, M H Bar, et al.
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaJ Clin Oncol. 1992 Feb;10(2):275-81.
Galkina O., Katinas E., Buratsova N. et al.
Recombinant human interleukin-2 in local treatment pf purulent sinusitis.
Immunology Letters. 2000. V. 73. № 2-3. P.219.
Galkina O., Lavrenova G., Katinas E. et al.
Local immunotherapy of purulent sinusitis by recombinant human interleukin-2.
Shock. 2000. V. 13. P. 165.
Galkina O.V., Petrov S.V., Smirnov M.N. et al.
Immunological effects following interleukin-2 therapy in patients with sepsis and peritonitis.
4th Intern. Congress on The Immune Consequences of Trauma, Shock and Sepsis. Munich, Germany, 1997. P. 879-883.
Galkina O.V., Zyeva Ye.Ye., Totolian A.A., Petrov S.V.
The immune controle of rIL-2 therapy in patients with severe peritonitis and surgical sepsis.
Advances in Critical Care Testing, the 1999 IFCC-AVL Award. Eds. W.F. List, M.M. Muller, A.St. John. P. 82-83.
Garibal J., Laforge M., Silvestre R. et al.
IL-2 Immunotherapy in Chronically SIV-infected Rhesus Macaques.Virol J. 2012 Sep 28;9:220. doi: 10.1186/1743-422X-9-220.
Gemlo BT, Palladino MA Jr, Jaffe HS, Espevik TP, Rayner AA.
Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.Cancer Res. 1988 Oct 15;48(20):5864-7. PMID: 3139285.
George S., Hutson T.E., Mekhail T. et al.
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.Cancer Chemother Pharmacol. 2008 Jul;62(2):347-54. Epub 2007 Oct 2.
Gizinger O.A., Egorova V.N., Trofimov V.I. 
PDF
Recombinant cytokines in the treatment of pneumonia. Clinical experience.
Journal of Interdisciplinary Approaches to Medicine. — Al-Farabi Kazakh National University. — 2021,V.1, I. 1.
Glassman AB.
Interleukin-2 and lymphokine activated killer cells: promises and cautions.Ann Clin Lab Sci. 1989 Jan-Feb;19(1):51-5. PMID: 2644890.
Graßhoff H, Comdühr S, Monne LR et al. PDF
Front. Immunol., 01 April 2021. Sec. Immunological Tolerance and Regulation. Volume 12. — 2021.
Gratama JW, Bruin RJ, Lamers CH et al.
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. PMID: 8485906; PMCID: PMC1554808.
Grinev M.V., Frolov G.M., Gromov M.I. et al.
Adoptive immunotherapy in the combined management of advanced colorectal cancer, complicated with acute intestinal obstruction.
J. Emerg. Surg. Int. Care. 1995. V.18. № 1/2. P.27-32.
Grinev V.V., Gromov M.I., Tarelkina M.N.
Use of Roncoleukin® (recombinant interleukin-2) in treatment of surgical septic patients.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 57 (R005).
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.